Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
GrantDeferred Stock Units · Derivative | 14,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002835 · doc4.xml · derivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,824 Underlying: Common Stock · 14,824 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC |
Carruthers WendySVP, Human Resources
|
GrantStock Option (Right to Buy) · Derivative | 27,654 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002833 · doc4.xml · derivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,654 Underlying: Common Stock · 27,654 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC |
Carruthers WendySVP, Human Resources
|
GrantDeferred Stock Units · Derivative | 7,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002833 · doc4.xml · derivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,412 Underlying: Common Stock · 7,412 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:29 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
GrantStock Option (Right to Buy) · Derivative | 35,398 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002832 · doc4.xml · derivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,398 Underlying: Common Stock · 35,398 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:29 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
GrantDeferred Stock Units · Derivative | 9,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002832 · doc4.xml · derivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,487 Underlying: Common Stock · 9,487 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:28 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
GrantStock Option (Right to Buy) · Derivative | 46,460 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002830 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,460 Underlying: Common Stock · 46,460 shares Expires 2030-02-18 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:28 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
GrantDeferred Stock Units · Derivative | 12,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002830 · doc4.xml · derivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,452 Underlying: Common Stock · 12,452 shares Expires 2024-02-18 F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:29 UTC |
Brennan Daniel J.EVP and CFO
|
GrantStock Option (Right to Buy) · Derivative | 55,309 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002831 · doc4.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,309 Underlying: Common Stock · 55,309 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:29 UTC |
Brennan Daniel J.EVP and CFO
|
GrantDeferred Stock Units · Derivative | 14,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002831 · doc4.xml · derivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,824 Underlying: Common Stock · 14,824 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:20 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionDeferred Stock Units · Derivative | 1,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002618 · doc4.xml · derivative · entry 5 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 1,199 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:20 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Tax withholdingCommon Stock | 367 | $42.31 | $15,527.77 |
DisclosureSEC source: 0001225208-20-002618 · doc4.xml · nonDerivative · entry 4 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,899 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:20 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionCommon Stock | 1,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002618 · doc4.xml · nonDerivative · entry 3 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionDeferred Stock Units · Derivative | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002614 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,983 Underlying: Common Stock · 1,661 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Tax withholdingCommon Stock | 824 | $42.31 | $34,863.44 |
DisclosureSEC source: 0001225208-20-002614 · doc4.xml · nonDerivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,171 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002614 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:20 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionDeferred Stock Units · Derivative | 1,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002620 · doc4.xml · derivative · entry 2 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,153 Underlying: Common Stock · 1,384 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:20 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionCommon Stock | 1,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002620 · doc4.xml · nonDerivative · entry 1 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:20 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionDeferred Stock Units · Derivative | 1,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002619 · doc4.xml · derivative · entry 5 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,538 Underlying: Common Stock · 1,845 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:20 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 1,028 | $42.31 | $43,494.68 |
DisclosureSEC source: 0001225208-20-002619 · doc4.xml · nonDerivative · entry 4 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,920.99 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:20 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 1,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002619 · doc4.xml · nonDerivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,948.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
Exercise / conversionDeferred Stock Units · Derivative | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002616 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,323 Underlying: Common Stock · 1,107 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
Tax withholdingCommon Stock | 396 | $42.31 | $16,754.76 |
DisclosureSEC source: 0001225208-20-002616 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,148 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
Exercise / conversionCommon Stock | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002616 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionDeferred Stock Units · Derivative | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002615 · doc4.xml · derivative · entry 5 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,306 Underlying: Common Stock · 2,768 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Pierce David AEVP,Pres MedSurg
|
Tax withholdingCommon Stock | 1,257 | $42.31 | $53,183.67 |
DisclosureSEC source: 0001225208-20-002615 · doc4.xml · nonDerivative · entry 4 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,051 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002615 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Monson JonathanVP, Corp Controller and CAO
|
Exercise / conversionDeferred Stock Units · Derivative | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002613 · doc4.xml · derivative · entry 3 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,215 Underlying: Common Stock · 738 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Monson JonathanVP, Corp Controller and CAO
|
Tax withholdingCommon Stock | 264 | $42.31 | $11,169.84 |
DisclosureSEC source: 0001225208-20-002613 · doc4.xml · nonDerivative · entry 2 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,127 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:19 UTC |
Monson JonathanVP, Corp Controller and CAO
|
Exercise / conversionCommon Stock | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002613 · doc4.xml · nonDerivative · entry 1 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionDeferred Stock Units · Derivative | 2,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002612 · doc4.xml · derivative · entry 6 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,091 Underlying: Common Stock · 2,030 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 926 | $42.31 | $39,179.06 |
DisclosureSEC source: 0001225208-20-002612 · doc4.xml · nonDerivative · entry 4 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,727 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002612 · doc4.xml · nonDerivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Exercise / conversionDeferred Stock Units · Derivative | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002611 · doc4.xml · derivative · entry 5 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,323 Underlying: Common Stock · 1,107 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Tax withholdingCommon Stock | 337 | $42.31 | $14,258.47 |
DisclosureSEC source: 0001225208-20-002611 · doc4.xml · nonDerivative · entry 4 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,532 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Exercise / conversionCommon Stock | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002611 · doc4.xml · nonDerivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionDeferred Stock Units · Derivative | 18,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002610 · doc4.xml · derivative · entry 5 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,371 Underlying: Common Stock · 18,457 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 8,195 | $42.31 | $346,730.45 |
DisclosureSEC source: 0001225208-20-002610 · doc4.xml · nonDerivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174,162 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 18,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002610 · doc4.xml · nonDerivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,182,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionDeferred Stock Units · Derivative | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002609 · doc4.xml · derivative · entry 5 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,306 Underlying: Common Stock · 2,768 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Mackey Edward FEVP, Operations
|
Tax withholdingCommon Stock | 1,257 | $42.31 | $53,183.67 |
DisclosureSEC source: 0001225208-20-002609 · doc4.xml · nonDerivative · entry 4 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,539 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:18 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionCommon Stock | 2,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002609 · doc4.xml · nonDerivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:10 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Exercise / conversionDeferred Stock Units · Derivative | 4,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · derivative · entry 9 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,843 Underlying: Common Stock · 4,614 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:10 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Tax withholdingCommon Stock | 2,278 | $42.31 | $96,382.18 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,051 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:10 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Exercise / conversionCommon Stock | 4,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:10 UTC |
Eddy Jodi EuerleSVP and CIO
|
Exercise / conversionDeferred Stock Units · Derivative | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002604 · doc4.xml · derivative · entry 3 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 Underlying: Common Stock · 923 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:10 UTC |
Eddy Jodi EuerleSVP and CIO
|
Tax withholdingCommon Stock | 330 | $42.31 | $13,962.30 |
DisclosureSEC source: 0001225208-20-002604 · doc4.xml · nonDerivative · entry 2 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,902 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:10 UTC |
Eddy Jodi EuerleSVP and CIO
|
Exercise / conversionCommon Stock | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002604 · doc4.xml · nonDerivative · entry 1 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:09 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionDeferred Stock Units · Derivative | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002603 · doc4.xml · derivative · entry 5 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,983 Underlying: Common Stock · 1,661 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:09 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 505 | $42.31 | $21,366.55 |
DisclosureSEC source: 0001225208-20-002603 · doc4.xml · nonDerivative · entry 4 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,821 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:09 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002603 · doc4.xml · nonDerivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.